Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease

Recruiting

• Conditions: Thyroid Dysfunction; Metabolic Dysfunction-Associated Fatty Liver Disease

• Registration Number: NCT06739330
• Lead Sponsor: Tanta University

Brief Summary

This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.

Detailed Description

One of the most common causes of chronic liver diseases worldwide is metabolic dysfunction-associated fatty liver disease (MAFLD), which affects about 30% of adults. Thyroid hormones are critical in maintaining metabolic homeostasis throughout life and are intimately linked to the liver.

Dysfunctions of the thyroid gland have been implicated as one of the most important risk factors of MAFLD due to its important role in the hepatic synthesis of fatty acid and cholesterol. Maintaining liver metabolism requires thyroid function to be normal, while thyroid disorders may lead to liver disease progression.

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-09
• Study First Submitted QC: 2024-12-12
• Study First Posted: 2024-12-18
• Study Start: 2024-12-19
• Last Update Submitted: 2024-12-19
• Last Update Posted: 2024-12-20
• Primary Completion: 2025-05-01
• Study Completion: 2025-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Age ≥ 18 years.
• Both sexes.
• Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).

Exclusion Criteria

• History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
• Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
• Viral hepatitis.
• Pregnant women.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Level of free triiodothyronine (FT3)	After the sample is taken (up to 5 minutes)	Free triiodothyronine (FT3) will be measured using chemiluminescent immunoassay analysis.

Secondary Outcome Measures

Name	Time	Method
Level of free thyroxine (FT4)	After the sample is taken (up to 5 minutes)	Free thyroxine (FT4) will be measured using chemiluminescent immunoassay analysis.
Level of thyroid stimulating hormone	After the sample is taken (up to 5 minutes)	Thyroid stimulating hormone will be measured using chemiluminescent immunoassay analysis.
Relation between gender and thyroid function	After the sample is taken (up to 5 minutes)	Relation between gender and thyroid function will be assessed.
Correlation between metabolic data and thyroid function tests	After the sample is taken (up to 5 minutes)	Correlation between metabolic data and thyroid function tests will be assessed.

Trial Locations

Locations (1)

Tanta University; 🇪🇬 Tanta, El-Gharbia, Egypt